XOOMAR
Get a free API key

Gain Therapeutics (GANX)

Gain Therapeutics on one page: short interest, daily short volume, fails to deliver, 13F holders, earnings dates and insider trades. Listed on Nasdaq.

Download CSV

3.2M

Short interest

settlement 2026-10-15

6.5

Days to cover

+0.6 days vs prior

66.0%

Short share of volume

2026-11-03

5,043

Fails to deliver

settlement 2026-10-07

Wed 11 Nov

Next earnings

estimated date

$0

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-03.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in GANX is 3,191,453 shares, up 304,302 shares over the last month. Over the last 48 readings it ranged from 198,826 shares (15 July 2025) to 3,869,330 shares (15 June 2026). At the reported average volume of 490K shares a day that is 6.5 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ganx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-153,191,453+4.4%490,2196.51
2026-09-303,056,188+5.8%515,3815.93
2026-09-152,887,151+3.3%325,1058.88
2026-08-312,795,819-5.3%365,4057.65
2026-08-142,952,391-8.1%604,0184.89
2026-07-313,213,359-10.4%483,1036.65
2026-07-153,588,085-0.6%886,1694.05
2026-06-303,608,175-6.8%1,998,0571.81
2026-06-153,869,330+21.0%638,3256.06
2026-05-293,198,541+1.2%829,4263.86
2026-05-153,160,772-8.2%437,7657.22
2026-04-303,442,408+3.3%543,7596.33
2026-04-153,331,182+1.5%574,9615.79
2026-03-313,282,560+14.2%814,7574.03
2026-03-132,873,797-0.3%799,8433.59
2026-02-272,883,705-5.1%706,1504.08
2026-02-133,039,619+2.1%513,1725.92
2026-01-302,976,352+19.9%795,3833.74
2026-01-152,482,134-6.9%1,355,6021.83
2025-12-312,666,410+28.6%2,698,1861.00
2025-12-152,073,310+64.5%1,377,9571.50
2025-11-281,260,732-29.2%987,1131.28
2025-11-141,781,339+95.6%1,538,1831.16
2025-10-31910,705-28.3%664,3581.37
2025-10-151,270,541+200.8%1,127,2251.13
2025-09-30422,327+12.0%644,8341.00
2025-09-15377,057+61.6%703,5861.00
2025-08-29233,336+10.6%391,9761.00
2025-08-15210,923-13.2%374,1391.00
2025-07-31242,995+22.2%280,1691.00
2025-07-15198,826-21.1%304,5161.00
2025-06-30252,124+8.5%342,9101.00
2025-06-13232,307-20.4%261,4161.00
2025-05-30291,844+0.6%189,1371.54
2025-05-15290,186-1.9%321,0271.00
2025-04-30295,777+5.7%280,0701.06
2025-04-15279,721-7.6%301,8531.00
2025-03-31302,677-7.3%277,7311.09
2025-03-14326,688-6.3%227,5101.44
2025-02-28348,828-24.5%286,7391.22
2025-02-14462,159+26.6%227,6652.03
2025-01-31365,119-2.5%172,7832.11
2025-01-15374,594+11.8%247,8521.51
2024-12-31335,214+0.2%263,8271.27
2024-12-13334,664-42.4%233,3791.43
2024-11-29580,553-19.2%212,0082.74
2024-11-15718,735+9.2%269,9912.66
2024-10-31658,341+15.1%416,0851.58

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 3 November 2026, the short share of GANX volume is 66.0%, up 33.1 points over the last five sessions. Over the last 30 readings it ranged from 33.0% (27 October 2026) to 80.3% (6 October 2026). The latest reading is 9.0 points above the 30-session average of 57.0%, on 120K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-0380K120K66.0%0
2026-11-0294K163K57.8%300
2026-10-30153K256K59.7%2,000
2026-10-2955K95K57.7%0
2026-10-28136K283K48.1%0
2026-10-27111K336K33.0%990
2026-10-26256K473K54.0%0
2026-10-23178K338K52.8%200
2026-10-221.3M2.0M63.4%0
2026-10-21156K397K39.4%1,000
2026-10-20104K305K34.2%2,731
2026-10-19199K392K50.8%0
2026-10-16161K273K58.9%303
2026-10-15202K394K51.3%6,400
2026-10-14261K541K48.1%43,925
2026-10-13269K573K46.9%9,941
2026-10-12138K189K73.1%0
2026-10-09149K187K79.6%1,727
2026-10-08112K231K48.2%0
2026-10-07132K215K61.4%0
2026-10-06320K398K80.3%0
2026-10-05103K191K53.8%0
2026-10-02152K269K56.6%0
2026-10-01205K295K69.5%0
2026-09-30263K483K54.3%100
2026-09-29456K804K56.7%1,909
2026-09-28224K311K72.0%1,800
2026-09-25138K191K72.4%700
2026-09-2497K199K48.5%0
2026-09-2390K148K60.7%650

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 7 October 2026, the fails-to-deliver balance in GANX is 5,043 shares, up 478 shares over the last settlement date. Over the last 30 readings it ranged from 60 shares (6 July 2026) to 200,220 shares (10 June 2026). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-10-075,043$1.67$8K
2026-09-144,565$1.75$8K
2026-08-24399$2.01$802
2026-08-171,424$2.12$3K
2026-08-144,211$2.17$9K
2026-08-0439,981$1.75$70K
2026-08-0340,846$1.68$69K
2026-07-3175,488$1.76$133K
2026-07-3062,736$1.69$106K
2026-07-2311,480$1.84$21K
2026-07-2239,647$1.84$73K
2026-07-172,977$1.66$5K
2026-07-161,598$1.68$3K
2026-07-1577,643$1.68$130K
2026-07-146,657$1.76$12K
2026-07-07250$1.81$453
2026-07-0660$1.91$115
2026-07-026,196$1.99$12K
2026-07-0136,114$2.03$73K
2026-06-3061,140$1.98$121K
2026-06-259,439$1.74$16K
2026-06-2436,950$1.77$65K
2026-06-221,103$1.88$2K
2026-06-184,722$1.78$8K
2026-06-178,726$1.79$16K
2026-06-1551,114$1.68$86K
2026-06-11106$1.64$174
2026-06-10200,220$1.65$330K
2026-06-099,452$1.69$16K
2026-06-057,038$1.86$13K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for GANX in the last 90 days. The most recent filings are listed below. Latest filing: Mack Gene (CFO and Interim CEO) on 2024-08-09.

DateInsiderTitleTypeSharesPriceValueOwned after
2024-08-09Mack GeneCFO and Interim CEOBuy14K$1.01$15K14K
2024-08-09Islam KhalidExecutive ChairmanBuy50K$1.00$50K50K
2024-07-01RICHMAN ERIC IDirectorBuy12K$1.21$15K290K
2024-07-01RICHMAN ERIC IDirectorBuy5K$1.23$6K278K
2024-03-28Riley Jeffrey ScottDirectorBuy30K$3.86$116K30K
2024-03-26Alder MatthiasChief Executive OfficerExercise or conversion637price not stated in the filingnot stated27K
2024-03-26Alder MatthiasChief Executive OfficerExercise or conversion19Kprice not stated in the filingnot stated26K
2024-03-26Alder MatthiasChief Executive OfficerExercise or conversion825price not stated in the filingnot stated27K
2024-03-26Alder MatthiasChief Executive OfficerTax withholding6K$4.06$25K21K
2023-12-21Alder MatthiasChief Executive OfficerSell206$2.46$5075K
2023-12-20Alder MatthiasChief Executive OfficerExercise or conversion637price not stated in the filingnot stated5K
2023-12-07Alder MatthiasChief Executive OfficerSell2K$2.50$5K5K
2023-10-01Alder MatthiasChief Executive OfficerExercise or conversion825price not stated in the filingnot stated7K
2023-09-20Alder MatthiasChief Executive OfficerExercise or conversion3Kprice not stated in the filingnot stated6K
2023-09-20RICHMAN ERIC IDirectorExercise or conversion55Kprice not stated in the filingnot stated273K
2023-07-01Alder MatthiasChief Executive OfficerExercise or conversion3Kprice not stated in the filingnot stated3K
2022-05-25RICHMAN ERIC ICHIEF EXECUTIVE OFFICERBuy2K$2.58$6K218K
2022-05-20RICHMAN ERIC ICHIEF EXECUTIVE OFFICERBuy9K$2.83$26K215K
2022-05-19Calabrese SalvatoreCHIEF FINANCIAL OFFICERBuy3K$8100.00$24.3Mn/a
2022-05-19Calabrese SalvatoreCHIEF FINANCIAL OFFICERBuy3K$2.70$8K3K
2022-05-19RICHMAN ERIC ICHIEF EXECUTIVE OFFICERBuy4K$2.71$11K206K
2021-08-16RICHMAN ERIC IChief Executive OfficerBuy5K$7.87$39K217K
2021-08-16RICHMAN ERIC IDirectorExercise or conversion5K$7.87$39K217K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

13F holders

Tracked managers holding GANX at their latest 13F. JSON

2 of the 30 tracked managers held GANX at their latest 13F, $1.5M in total at quarter-end prices. Greenlight Capital (DME Capital) is the largest at $1.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 0 cut.

FundQuarterSharesValueOf portfolioChange in shares
Greenlight Capital (DME Capital)2026-06-30566K$1.1M0.03%0
Citadel Advisors2026-06-30155K$314K0.00%+130K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Gain Therapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Gain Therapeutics (GANX), SEC CIK 1819411, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-07.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2024-08-09.JSON and CSV
Company record
EDGAR filing index for CIK 1819411Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other company pages

Datasets

Frequently Asked Questions

How much of GANX is sold short?
3,191,453 shares were held short at the 2026-10-15 settlement, 6.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is GANX's daily short volume?
On 2026-11-03, 79,541 of the 120,483 GANX shares reported to FINRA were sold short, 66.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does GANX have fails to deliver?
The SEC's latest file shows 5,043 GANX shares failed to deliver at settlement 2026-10-07. Fails are reported per settlement date and published twice a month with a lag.
Are GANX insiders buying or selling?
No open-market insider trades were reported for GANX in the last 90 days. The most recent filings are listed below. Latest filing: Mack Gene (CFO and Interim CEO) on 2024-08-09.
Which tracked 13F managers own GANX?
2 of the 30 tracked 13F managers held GANX shares at their latest filing, $1.5M in all. The largest: David Einhorn's Greenlight Capital (DME Capital) (566K shares, $1.1M), Ken Griffin's Citadel Advisors (155K shares, $314K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.